AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27072963 — intervention group
Group type: COMPARATOR
Intervention: Non-implantation (NIP)
Number of subjects: 224
Study 24161233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid screening (PCR testing for MRSA and VRE, chromogenic screening for HRE)
Number of subjects: 13
Study 24161233 — intervention group
Group type: COMPARATOR
Intervention: Conventional screening (chromogenic screening for MRSA and VRE)
Number of subjects: 13
Study 24161233 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine body-washing and hand hygiene improvement
Number of subjects: 13
Study 22393898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 30
Study 22393898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 100 mg
Number of subjects: 30
Study 22393898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22393898 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 30
Study 22393898 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg co-administered with ketoconazole 400 mg
Number of subjects: 30
Study 21336170 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-open group (hinge at inner margin of lateral mass)
Number of subjects: 102
Study 21336170 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-open group (hinge at lamina margin)
Number of subjects: 102
Study 21336170 — intervention group
Group type: COMPARATOR
Intervention: Narrow-open group
Number of subjects: 102
Study 21336170 — intervention group
Group type: COMPARATOR
Intervention: Wide-open group
Number of subjects: 102
Study 16670121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediacel vaccine
Number of subjects: 241
Study 16670121 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria-tetanus-whole-cell pertussis-Haemophilus influenzae type b (DTwP-Hib) vaccine
Number of subjects: 241
Study 16670121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediacel with meningococcal group C conjugate with diphtheria-derived protein CRM(197) (MCC-CRM)
Number of subjects: 241
Study 16670121 — intervention group
Group type: COMPARATOR
Intervention: DTwP-Hib with meningococcal group C conjugate with diphtheria-derived protein CRM(197) (MCC-CRM)
Number of subjects: 241
Study 16670121 — intervention group
Group type: COMPARATOR
Intervention: DTwP-Hib vaccine
Number of subjects: 241
Study 16670121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediacel with meningococcal group C conjugate with tetanus toxoid (MCC-TT)
Number of subjects: 241
Study 16670121 — intervention group
Group type: COMPARATOR
Intervention: DTwP-Hib with meningococcal group C conjugate with tetanus toxoid (MCC-TT)
Number of subjects: 241
Study 16670121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediacel and DTwP-Hib with MCC-CRM
Number of subjects: 241
Study 16670121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediacel and DTwP-Hib
Number of subjects: 241
Study 15640461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran oil diet (1/3 of total dietary fat)
Number of subjects: 40
Study 15640461 — intervention group
Group type: COMPARATOR
Intervention: Defatted rice bran diet (13-22 g dietary fiber/d)
Number of subjects: 40
Study 12198012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation of 80 mg Cu (as copper sulfate). kg body wt(‐1). d(‐1) for 15 d
Number of subjects: 39
Study 12198012 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 39
Study 10192200 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a alone (4.5 MIU thrice weekly for 6 months)
Number of subjects: 53
Study 10192200 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a plus ribavirin (1000-1200 mg/day in combination with the same dose of interferon-alpha2a for 6 months)
Number of subjects: 53
Study 10192200 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha2a plus ribavirin (1000-1200 mg/day)
Number of subjects: 53
Study 7587687 — intervention group
Group type: EXPERIMENTAL
Intervention: fat‐glucose‐based group (intralipid)
Number of subjects: 17
Study 7587687 — intervention group
Group type: COMPARATOR
Intervention: glucose‐based group (control)
Number of subjects: 17
Study 2129094 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticonvulsant therapy
Number of subjects: 0
Study 6991560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed teeth (molars)
Number of subjects: 0
Study 6991560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed teeth (premolars)
Number of subjects: 0
Study 6991560 — intervention group
Group type: COMPARATOR
Intervention: Molar sealant failures
Number of subjects: 0
Study 6991560 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (unsealed)
Number of subjects: 0
Study 31891212 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% Alfalfa Hay (AH)
Number of subjects: 16
Study 31891212 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Common Vetch Hay (CVH)
Number of subjects: 16
Study 31891212 — intervention group
Group type: COMPARATOR
Intervention: 0% Oat Hay (Control)
Number of subjects: 16
Study 31891212 — intervention group
Group type: EXPERIMENTAL
Intervention: 8%, 16%, 24% Alfalfa Hay (AH)
Number of subjects: 16
Study 31891212 — intervention group
Group type: EXPERIMENTAL
Intervention: 10%, 20%, 30% Common Vetch Hay (CVH)
Number of subjects: 16
Study 31740877 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention (group 2)
Number of subjects: 550
Study 25282520 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg every 4 weeks for 12 weeks
Number of subjects: 50
Study 25282520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25350595 — intervention group
Group type: EXPERIMENTAL
Intervention: Local melatonin (3 mg)
Number of subjects: 10
Study 23226013 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin taken daily for one year
Number of subjects: 1037
Study 23226013 — intervention group
Group type: COMPARATOR
Intervention: Mannose-binding lectin deficiency
Number of subjects: 1037
Study 19019050 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol added to 0.25% bupivacaine
Number of subjects: 30
Study 19019050 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.25% bupivacaine alone)
Number of subjects: 30
Study 17450417 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI) focused on tobacco, alcohol, diet, weight, sun exposure, and work risk, delivered four times over 18 months, one every six months.
Number of subjects: 3031
Study 17450417 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI)
Number of subjects: 3031
Study 15342891 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated asthma detection algorithm with 3 questions (question 1: asthma in the past 2 years, question 4: cough, chest tightness, trouble breathing, or wheezing with exercise, question 6: same symptoms in the morning or day in the past 4 weeks)
Number of subjects: 401
Study 15342891 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete asthma detection algorithm
Number of subjects: 401
Study 15342891 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma detection tool
Number of subjects: 401
Study 15342891 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of the questionnaires
Number of subjects: 401
Study 11271696 — intervention group
Group type: EXPERIMENTAL
Intervention: SNACs established in intervention schools
Number of subjects: 16
Study 9777182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 30
Study 8150847 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapeutic ultrasound followed by 10 minutes of passive stretching
Number of subjects: 14
Study 8150847 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound treatments and stretching
Number of subjects: 14
Study 3170408 — intervention group
Group type: EXPERIMENTAL
Intervention: met‐hGH (2.67 mg/0.5 ml diluent, 3 days/wk)
Number of subjects: 8
Study 3170408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bacteriostatic water, 0.5 ml, 3 days/wk)
Number of subjects: 8
Study 3170408 — intervention group
Group type: EXPERIMENTAL
Intervention: met‐hGH
Number of subjects: 8
Study 31154006 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide sodium
Number of subjects: 0
Study 31154006 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide
Number of subjects: 0
Study 28006886 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg dexmedetomidine
Number of subjects: 144
Study 28006886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg dexmedetomidine
Number of subjects: 144
Study 28006886 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane at 0.7 MAC
Number of subjects: 144
Study 28006886 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 144
Study 28006886 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane at 1.4 MAC
Number of subjects: 144
Study 28006886 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane at 2.0 MAC
Number of subjects: 144
Study 25856121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 555
Study 25856121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 24235903 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg taken 0 hours before bedtime
Number of subjects: 0
Study 24235903 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg taken 3 hours before bedtime
Number of subjects: 0
Study 24235903 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg taken 6 hours before bedtime
Number of subjects: 0
Study 24235903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21336736 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrodin (40 mg/kg)
Number of subjects: 200
Study 21336736 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 200
Study 19874989 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1421
Study 19874989 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1421
Study 19874989 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment resolution at 4 h
Number of subjects: 1421
Study 16963221 — intervention group
Group type: EXPERIMENTAL
Intervention: Victims of interpersonal trauma
Number of subjects: 81
Study 16963221 — intervention group
Group type: COMPARATOR
Intervention: Non-victims of interpersonal trauma
Number of subjects: 81
Study 16963221 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma status (victims vs non-victims)
Number of subjects: 81
Study 15831694 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 7800
Study 15831694 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 7800
Study 15831694 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 7800
Study 12578152 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg after an overnight fast
Number of subjects: 18
Study 12578152 — intervention group
Group type: COMPARATOR
Intervention: Telithromycin 800 mg after a standard high-fat breakfast
Number of subjects: 18
Study 12578152 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg (both fasting and non-fasting)
Number of subjects: 18
Study 10099075 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol/6.25 mg HCTZ (n = 155)
Number of subjects: 541
Study 10099075 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine (n = 154)
Number of subjects: 541
Study 10099075 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (n = 155)
Number of subjects: 541
Study 10099075 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 79)
Number of subjects: 541
Study 7857500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract LI 160 (300 mg three times daily for 4 weeks)
Number of subjects: 39
Study 7857500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 2477463 — intervention group
Group type: EXPERIMENTAL
Intervention: Water‐Suppressed Proton Nuclear Magnetic Resonance Spectroscopy (1 HNMR) of plasma lipoproteins
Number of subjects: 75
Study 1067690 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with penicillins or cephalosporins
Number of subjects: 132
Study 1067690 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 132
Study 31657590 — intervention group
Group type: EXPERIMENTAL
Intervention: ENHANCE intervention program (12-week comprehensive program)
Number of subjects: 155
Study 31657590 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 155
Study 31657590 — intervention group
Group type: EXPERIMENTAL
Intervention: ENHANCE intervention (original treatment condition)
Number of subjects: 155
Study 30112788 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Member Education Program (FMEP)
Number of subjects: 144
Study 30112788 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 144
Study 28116876 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI® technique in combination with a standardized APT program
Number of subjects: 24
Study 28116876 — intervention group
Group type: COMPARATOR
Intervention: APT program
Number of subjects: 24
Study 26162594 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel size 2 (group I)
Number of subjects: 0
Study 26162594 — intervention group
Group type: COMPARATOR
Intervention: CLMA size 2 (group II)
Number of subjects: 0
Study 22251226 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW)
Number of subjects: 0
Study 22251226 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly (BIW)
Number of subjects: 0
Study 21641077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser therapy (FLT) at 10 mJ/microbeam, coverage 35% to 45%, and topical bleaching
Number of subjects: 11
Study 21641077 — intervention group
Group type: COMPARATOR
Intervention: Topical bleaching alone
Number of subjects: 11
Study 21641077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser therapy (FLT)
Number of subjects: 11
Study 18516011 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 day-sequential therapy (20 mg of omeprazole, 1.0 g of amoxicillin for the first 5 days, followed by 20 mg of omeprazole, 500 mg of clarithromycin, 500 mg of metronidazole for the remaining 5 days)
Number of subjects: 158
Study 18516011 — intervention group
Group type: COMPARATOR
Intervention: PPI-based triple therapy (20 mg of omeprazole, 1.0 g of amoxicillin, 500 mg of clarithromycin for 1 week)
Number of subjects: 158
Study 16521033 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 58
Study 16521033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 58
Study 12914361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision (ultrasonic hook)
Number of subjects: 34
Study 12914361 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostasis
Number of subjects: 34
Study 10541299 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa (100 U/kg)
Number of subjects: 11
Study 10541299 — intervention group
Group type: EXPERIMENTAL
Intervention: NESP (equivalent peptide mass) intravenous
Number of subjects: 11
Study 10541299 — intervention group
Group type: EXPERIMENTAL
Intervention: NESP (equivalent peptide mass) subcutaneous
Number of subjects: 11
Study 7604351 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Percutaneous Lumbar Discectomy (APLD)
Number of subjects: 71
Study 7604351 — intervention group
Group type: COMPARATOR
Intervention: Lumbar Microdiscectomy
Number of subjects: 71
Study 2233588 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral colonic lavage
Number of subjects: 90
Study 2233588 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna preparation
Number of subjects: 90
Study 2233588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined laxative agent
Number of subjects: 90
Study 263355 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (1.0 g)
Number of subjects: 14
Study 31422201 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 95
Study 31422201 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 95
Study 28318988 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (2 mg kg−1 intravenously)
Number of subjects: 168
Study 28318988 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2 mg kg−1 intravenously)
Number of subjects: 168
Study 28318988 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 168
Study 25311220 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) for DCIS.
Number of subjects: 1046
Study 23102521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (up to ten sessions over 3 months)
Number of subjects: 113
Study 19602734 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 46
Study 19602734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 46
Study 19602734 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 46
Study 17877624 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bleaching treatment for teeth whitening
Number of subjects: 172
Study 15086494 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bicarbonate dialysis (BD)
Number of subjects: 12
Study 15086494 — intervention group
Group type: COMPARATOR
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 12
Study 15086494 — intervention group
Group type: EXPERIMENTAL
Intervention: Model simulations
Number of subjects: 12
Study 12471289 — intervention group
Group type: COMPARATOR
Intervention: Endurance Training (ET)
Number of subjects: 20
Study 12471289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Endurance and Strength Training (CT)
Number of subjects: 20
Study 12471289 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CT vs ET
Number of subjects: 20
Study 9806587 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum hCG measurements
Number of subjects: 354
Study 9806587 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated serum hCG measurements
Number of subjects: 354
Study 9806587 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hCG concentration rise
Number of subjects: 354
Study 7895756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer solution
Number of subjects: 20
Study 7895756 — intervention group
Group type: COMPARATOR
Intervention: serum preparation (BISEKO)
Number of subjects: 20
Study 2565392 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of metoprolol p.o.
Number of subjects: 6
Study 2565392 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of oxprenolol p.o.
Number of subjects: 6
Study 2565392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 478263 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ribonuclease activity test
Number of subjects: 62
Study 478263 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 62
Study 478263 — intervention group
Group type: COMPARATOR
Intervention: Patients in remission from ovarian cancer
Number of subjects: 62
Study 30940676 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal platelet transfusion (to maintain a platelet count >100,000 per µL)
Number of subjects: 44
Study 30940676 — intervention group
Group type: COMPARATOR
Intervention: Standard platelet transfusion criteria
Number of subjects: 44
Study 30940676 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal platelet transfusion
Number of subjects: 44
Study 28117496 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐pulsed fractional CO2 laser applications (10,600 nm, density of 20%, energy of 10 mJ, scanner of 03 × 03 mm, pulse repetition time of 0.3 seconds)
Number of subjects: 42
Study 28117496 — intervention group
Group type: COMPARATOR
Intervention: Silicone gel
Number of subjects: 42
Study 25889705 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid-sparing conformal radiotherapy
Number of subjects: 0
Study 24021602 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical vasomotion stimulation
Number of subjects: 2
Study 24021602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 21831465 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-CT (radiotherapy and chemotherapy) - 64Gy in 5 weeks with synchronous CDDP 100mg/m² on days 2, 16, and 30 and 5FU 1000mg/m² on days 1-5 and 29-33, followed by two adjuvant cycles of CDDP-5FU for good responders.
Number of subjects: 109
Study 21831465 — intervention group
Group type: COMPARATOR
Intervention: Accelerated RT - 64Gy in 3 weeks (control arm).
Number of subjects: 109
Study 19720908 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg by mouth twice daily for 4 to 6 weeks
Number of subjects: 64
Study 19720908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19720908 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 64
Study 17043926 — intervention group
Group type: EXPERIMENTAL
Intervention: 10/20 mg Memantine per day
Number of subjects: 40
Study 17043926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17043926 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 40
Study 16481295 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2) on days 1 and 8, and Carboplatin (target AUC of 5.0 mg/ml) on day 1, in a 21‐day cycle
Number of subjects: 20
Study 16481295 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Carboplatin combination chemotherapy
Number of subjects: 20
Study 12934847 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib combination vaccine administered in a single injection
Number of subjects: 60
Study 12934847 — intervention group
Group type: COMPARATOR
Intervention: Separate injection of DTaP-IPV and Hib
Number of subjects: 60
Study 10546697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dose of recombinant leptin
Number of subjects: 127